Amrutanjan Health Care Limited · NSE:AMRUTANJAN
Amrutanjan Health Care — Q3 FY21 Earnings Presentation
15 slides from Amrutanjan Health Care's earnings presentation, Feb 11, 2021
Slide 1: Stock exchange covering letter for investor presentation
AHCL/ SE/ 57/2020-21 February 11, 2021 The National Stock Exchange of India Limited | BSE Limited “Exchange Plaza”, C-1, Block G Department of Corporate Services Bandra-Kurla Complex, Bandra (E) 1st Floor, Mumbai 400 051 P.J. Towers, Dalal Street, ISIN: INEO98F01031 Mumbai 400 001 Symbol : AMRUTANJA
Slide 2: Amrutanjan Health Care Limited Investor Presentation
Amrutanjan Health Care Limited Investor Presentation – Quarter & Period Ended 31st December 2020 Date: 11th February 2021
Slide 3: Contents
Contents a. Business Update b. YTD Dec’20 Performance c. Q3 FY21 Performance d. Way Forward Investor Presentation | Quarter & Period Ended 31st December 2020 2
Slide 4: Business Update
Business Update Investor Presentation | Quarter & Period Ended 31st December 2020 3
Slide 5: Business Update
Business Update • Despite restrictions for field force during lockdown, our wholesale channel was picking up. This shows our Brand strength. • The increase in purchase volume by the distributors has contributed to the growth factor. • Consumers’ current preference of Balms over Tablets remains to be
Slide 6: YTD Dec'20 Performance
YTD Dec’20 Performance Investor Presentation | Quarter & Period Ended 31st December 2020 5
Slide 7: Financials – YTD Dec'20
Financials – YTD Dec’20 (Rs. in Crores) Gross Sales Profit Before Tax 263.04 68.19 222.72 23.82 YTD Dec'20 YTD Dec'19 YTD Dec'20 YTD Dec'19 Growth: 18.10% Growth: 186.27% Gross Sales - E Comm. Profit After Tax 4.00 3.41 50.96 3.50 3.00 2.50 2.00 1.50 1.23 17.19 1.00 0.50 - YTD Dec'20 YTD Dec'19 YTD
Slide 8: Financials – YTD Dec'20 – OTC Division
Financials – YTD Dec’20 – OTC Division (Rs. in Crores) Gross Sales - OTC Costs: 252.44 206.76 • OTC sales has grown by 22.09% for YTD Dec’20 even though in Q1 sales was affected due to Covid 19 lockdown. YTD Dec'20 YTD Dec'19 Growth: 22.09% • Key raw material prices including Menthol are lower when
Slide 9: Financials – YTD Dec'20 – Beverage Division
Financials – YTD Dec’20 – Beverage Division (Rs. in Crores) Gross Sales - Beverages 14.04 9.64 Costs: • Gross Margin has improved by YTD Dec'20 YTD Dec'19 562 basis points when compared to YTD Dec’19 Growth: -31.34% mainly due to product mix. Gross Sales - Electro Plus • Advertisement spends is at 6
Slide 10: Q3 FY21 Performance
Q3 FY21 Performance Investor Presentation | Quarter & Period Ended 31st December 2020 9
Slide 11: Financials – Q3 FY21
Financials – Q3 FY21 (Rs. in Crores) Profit Before Tax Profit After Tax 28.14 20.99 12.60 9.49 Q3 FY21 Q3 FY20 Q3 FY21 Q3 FY20 Growth: 21.67% Growth: 123.33% Growth: 121.18% Investor Presentation | Quarter & Period Ended 31st December 2020 10
Slide 12: Financials – Q3 FY21
Financials – Q3 FY21 (Rs. in Crores) Gross Sales - OTC Gross Sales - Comfy Gross Sales - Beverages 107.62 16.32 88.61 2.59 11.57 1.84 Q3 FY21 Q3 FY20 Q3 FY21 Q3 FY20 Q3 FY21 Q3 FY20 Growth: 21.45% Growth: 41.05% Growth: 40.76% Investor Presentation | Quarter & Period Ended 31st December 2020 11
Slide 13: Way Forward
Way Forward Investor Presentation | Quarter & Period Ended 31st December 2020 12
Slide 14: Way Forward
Way Forward We remain focused on executing our key priorities: • Complete Q4 with same growth momentum • Expand distribution • Strengthen Beverage business • Grow E-Commerce vertical • Costs control Investor Presentation | Quarter & Period Ended 31st December 2020 13
Slide 15: Investor Presentation | Quarter & Period Ended 31st December 2020
Investor Presentation | Quarter & Period Ended 31st December 2020 14
Amrutanjan Health Care — Q3 FY21 Earnings Presentation on 6ix